ERYTECH Announces Publication of Positive Results from Eryaspase Phase 2 Trial in Hypersensitive ALL in the British Journal of Haematology

Post author:Marianne Duparc
Post published:April 6, 2022
Post category:Newsroom

The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option for acute lymphoblastic leukemia (ALL) patients with hypersensitivity to PEG-asparaginase

You Might Also Like

ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2021

REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022

ERYTECH to Participate in Upcoming Virtual Investor Conferences in March